angiotensin converting enzyme inhibitors (perindopril, 4 mg/d), plus discretional indapamide
DISEASE INTERVENTION COMPARISON RESULTS
Lancet. 2001 Sep 29;358(9287):1033-41 Randomized Controlled Trial, Multicenter Study
IN stroke, hypertension, primary, non-hypertensive patients The Use of
angiotensin converting enzyme inhibitors (perindopril, 4 mg/d), plus discretional indapamide
As Prevention, Secondary
Is better Than
placebo
To reduce stroke (either ischemic or haemorrhagis) at 4 years: 10% with perindopril VS 14% with placebo. Also, it reduced major vascular events, but not mortality.